ArticleTherapeutic innovation & regulatory science2025
Development of a Safety Toolkit to Influence Inclusion Barriers for Adolescents and Young Adults (AYA) in Adult Clinical Trials.
Article in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lack of long-term safety data for the AYA population has been identified as a key area that reduces enrolment of AYA in adult oncology clinical trials. Here we describe a potential safety assessment solution, from a pharmacovigilance and clinical patient safety perspective, to enhance the inclusion of adolescents into adult oncology trials. To help bridge gaps in safety data that limit AYA participation, a Patient Safety Oncology Toolkit for AYA patients has been developed. The safety toolkit includes recommended additional clinical study protocol templated wording for assessment and management of general AYA-related risks for oncology agents, including infertility, growth and development, new primary malignancies, and neurocognitive effects. There is also recommended language to incorporate into the study protocol for investigational product specific risk considerations based on impacted organ systems. Using the safety toolkit, a key deliverable from the evaluation of the risks is the generation of a safety go, or no-go, Red-Amber-Green (RAG) rating for each study. The RAG rating scale is intended to summarize the scope and severity of any specific treatment-related safety concerns and helps standardize company governance and investment decisions. This toolkit is intended to allow teams to safely include AYA individuals in adult oncology studies and allow this population better access to life-changing medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.